| Revenue growth | 18% for FY26; Q4 YoY growth at 26%. |
|---|---|
| Margins | EBITDA margins expanded 420 bps to 43.4% in FY26. |
| Order book | Flow business for specialty ingredients; long-term visibility in CRDMO. |
| Demand visibility | Strong; restocking by customers follows prior destocking phase. |
| Management confidence | High; confident in 20%+ long-term growth trajectory. |
Growth
FY26 revenue grew 18% YoY to ₹2,124cr; PAT increased 31% to ₹592cr with 26% margins.
Outlook
Unit 4 capex of ₹1,200cr planned for FY27-28; targeting 20% long-term revenue growth and sustained high margins.
Risks
Challenges include inflationary pressures, geopolitical uncertainties (Middle East war), and potential capacity cannibalization by NCE projects.
Earnings Call filed with BSE, NSE: ANTHEM. Summary written with AI assistance from the document.
Anthem Biosciences Ltd: key numbers
- Share price
- ₹890.35
- Market cap
- ₹50,144 Cr
- Revenue (annual)
- ₹2,124 Cr
- Net profit (annual)
- ₹591.8 Cr
- P/E (TTM)
- 87.1×Sector 47.4×
- Promoter holding
- 71.42%-3.26% QoQ
- FII holding
- 2.57%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Anthem Biosciences Ltd
All →Anthem Biosciences Other Announcement
Designated Person Viridity Tone LLP sold shares of Anthem Biosciences Ltd worth ₹82.67 Crore via market sale.
- Value
- ₹82.67 Cr
Anthem Biosciences Legal & Regulatory
Anthem Biosciences Ltd announced the settlement of an upside sharing amount of ₹127.68 Crore related to a prior divestment, following shareholder approval.
- Value
- ₹127.7 Cr
Anthem Biosciences Management Change
Anthem Biosciences appointed S.R. Batliboi & Associates LLP as Statutory Auditor and noted director changes, including a rotation and continuation of directorship.
Anthem Biosciences Annual General Meeting
Anthem Biosciences held its 20th AGM on July 22, 2026. Shareholders approved all business resolutions, including financial statements, dividend declaration, and statutory auditor appointments.
Anthem Biosciences Earnings Call Transcript: Key Takeaways
Revenue fell 25% YoY due to deferred deliveries, though management claims a record order book will drive second-half recovery. While EBITDA margins remain high at 39.6%, the quarter reflects high lumpiness in the CRDMO business.
Anthem Biosciences Results Update
Anthem Biosciences reported Q1FY27 revenue of ₹418.2 Crore and profit after tax of ₹119.9 Crore. The company continues its focus on margin improvement and cost efficiencies.